Axonics Modulation

$50.67 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Axonics Modulation

Axonics, Inc., formerly Axonics Modulation Technologies, Inc., is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. It has two clinical studies relating to its r-SNM System: a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. SNM therapy consists of two phases: an evaluation period, also called the external trial period, and a permanent implant for those patients who experience a successful external trial period. Its product offering also include Bulkamid, which is used to treat patients with stress urinary incontinence.

Stock Analysis

last close $49.33
1-mo return -9.4%
3-mo return -26.5%
avg daily vol. 463.47T
52-week high 79.81
52-week low 46.96
market cap. $2.3B
forward pe -
annual div. -
roe -19.5%
ltg forecast -
dividend yield -
annual rev. $162M
inst own. -

Subscribe now for daily local and international financial news